Sugi Predict

Sugi Predict / Compounds / SCHEMBL175752

SCHEMBL175752

SCHEMBL175752

CC(Nc1cscn1)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.42
▸ KDM4E B2RXH2 1/20 0.40
▸ MCL1 Q07820 5/20 0.39
▸ BCL2 P10415 2/20 0.39
▸ HPGD P15428 1/20 0.37
▸ SCN1A P35498 6/20 0.36
▸ SCN5A Q14524 6/20 0.36
▸ SCN8A Q9UQD0 6/20 0.36
▸ KDM4C Q9H3R0 1/20 0.36
▸ SCN1B Q07699 2/20 0.34
▸ SCN9A Q15858 2/20 0.34
▸ NR1I2 O75469 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ SCN2A Q99250 1/20 0.34
▸ TSHR P16473 1/20 0.33
▸ HCAR3 P49019 1/20 0.33
▸ BCL2L1 Q07817 1/20 0.33
▸ MAP3K5 Q99683 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL175753 1.00 ALDH1A1 (0.42) ALDH1A1KDM4EMCL1BCL2HPGD
SCHEMBL3516836 1.00 ALDH1A1 (0.42) ALDH1A1KDM4EMCL1BCL2HPGD
Hydrochloric Acid SCHEMBL7300448 0.98 ALDH1A1 (0.41) ALDH1A1KDM4EMCL1BCL2HPGD
SCHEMBL7288378 0.84 PIK3CA (0.36) ALDH1A1KDM4ESCN1ASCN5ASCN8A
SCHEMBL6211278 0.83 SCN9A (0.35) ALDH1A1KDM4ESCN1ASCN5ASCN8A
SCHEMBL6616473 0.83 SCN9A (0.35) ALDH1A1KDM4ESCN1ASCN5ASCN8A
Hydrochloric Acid SCHEMBL6498236 0.81 SCN9A (0.34) ALDH1A1KDM4ESCN1ASCN5ASCN8A
Gabapentin SCHEMBL3169310 0.78 ALDH1A1 (0.48) ALDH1A1KDM4EMCL1BCL2HPGD
SCHEMBL7299956 0.76 KDM4E (0.35) ALDH1A1KDM4EHPGDSCN1ASCN5A
SCHEMBL9217841 0.74 FPR2 (0.32) SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 488 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4650362-A1 NEUROPROTECTIVE PSD-95 POLYPEPTIDE INHIBITOR AND USE THEREOF Beijing Tuo Jie Biopharmaceutical Co. Ltd. (CN) 2025-11-19 — — EP claimed
WO-2024149230-A1 NEUROPROTECTIVE PSD-95 POLYPEPTIDE INHIBITOR AND USE THEREOF 北京拓界生物医药科技有限公司 2024-07-18 — — WO claimed
EP-3970801-A1 RAS INHIBITORY PEPTIDE Ichimaru Pharcos Co., Ltd. (JP) 2022-03-23 — — EP claimed
CN-113727991-A Ras inhibitory peptide 一丸自然美健有限公司 2021-11-30 — — CN claimed
EP-3464324-B1 ANGIOTENSIN-1-RECEPTOR ANTAGONISTS FERRING BV (NL) 2021-04-07 — — EP claimed
CN-112279888-A Polypeptide inhibitor of APC/Asef interaction and application thereof 上海交通大学医学院 2021-01-29 — — CN claimed
CN-112209991-A Tripeptide inhibitor of APC/Asef interaction and application thereof 上海交通大学医学院 2021-01-12 — — CN claimed
WO-2020230780-A1 Ras INHIBITORY PEPTIDE 一丸ファルコス株式会社 2020-11-19 — — WO claimed
US-20200102348-A1 ANGIOTENSIN-1-RECEPTOR ANTAGONISTS FERRING B.V. (NL) 2020-04-02 — — US claimed
US-10344054-B2 Angiotensin-1-receptor antagonists FERRING B.V. (NL) 2019-07-09 — — US claimed
WO-1996040741-A1 PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS ORTHO PHARMACEUTICAL CORPORATION (US) 1996-12-19 — — WO claimed
WO-1996040742-A1 PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATEDDISORDERS ORTHO PHARMACEUTICAL CORPORATION (US) 1996-12-19 — — WO claimed
US-5523308-A SERINE PROTEASES INHIBITORS; ORAL ANTICOAGULANTS; CHEMICAL INTERMEDIATES; DIPEPTIDES ORTHO PHARMACEUTICAL CORPORATION 1996-06-04 — — US claimed
EP-0373549-B1 AMINO ACID DERIVATIVES WITH ENZYME-INHIBITING PROPERTIES, PROCESS TO SYNTHETISE THEM, COMPOSITION CONTAINING THEM AND THEIR USE HOECHST AKTIENGESELLSCHAFT (DE) 1993-09-01 — — EP claimed
WO-1992007845-A1 DERIVATIVES OF AMINO ACIDS AS INHIBITORS OF RENIN, METHODS FOR THEIR PREPARATION, MEDICAMENTS CONTAINING THEM AND THEIR USE HOECHST AKTIENGESELLSCHAFT (DE) 1992-05-14 — — WO claimed
EP-0483403-A1 Derivatives of amino acids as inhibitors of renin, methods for their preparation, medicaments containing them and their use HOECHST AKTIENGESELLSCHAFT (DE) 1992-05-06 — — EP claimed
EP-0417698-A2 Amino acid derivatives having renin-inhibiting activity, process for their preparation, agents containing them, and their use HOECHST AKTIENGESELLSCHAFT (DE) 1991-03-20 — — EP claimed
EP-0373549-A2 Amino acid derivatives with enzyme-inhibiting properties, process to synthetise them, composition containing them and their use HOECHST AKTIENGESELLSCHAFT (DE) 1990-06-20 — — EP claimed
EP-0372537-A2 Urea derivatives of dipeptides with enzyme-inhibiting properties, process to make them, compositions containing them and their use HOECHST AKTIENGESELLSCHAFT (DE) 1990-06-13 — — EP claimed
EP-0370383-A2 Renin-inhibiting dipeptides, process to make them, compositions containing them and their use HOECHST AKTIENGESELLSCHAFT (DE) 1990-05-30 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200102348-A1 ANGIOTENSIN-1-RECEPTOR ANTAGONISTS AGTR1, AGTR2, REN ALDH1A1 577/4885KDM4E 2299/4885MCL1 4090/4885
US-10344054-B2 Angiotensin-1-receptor antagonists AGTR1, AGTR2, AGT ALDH1A1 541/4885KDM4E 2970/4885MCL1 4173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.